NCT03978832View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

PHASE4CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

June 28, 2019

Primary Completion Date

May 12, 2020

Study Completion Date

May 12, 2020

Conditions
Schizophrenia
Interventions
DRUG

PERSERIS

PERSERIS is an extended-release SC injectable suspension administered once-monthly

DRUG

Risperidone

Oral risperidone

Trial Locations (1)

92845

Collaborative Neuroscience Network, Garden Grove

Sponsors

Lead Sponsor

Indivior Inc.
All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT03978832 - Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone | Biotech Hunter | Biotech Hunter